These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 9489640)

  • 1. Granulocyte-macrophage colony-stimulating factor-associated histiocytosis and capillary-leak syndrome following autologous bone marrow transplantation: two case reports and a review of the literature.
    Al-Homaidhi A; Prince HM; Al-Zahrani H; Doucette D; Keating A
    Bone Marrow Transplant; 1998 Jan; 21(2):209-14. PubMed ID: 9489640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe hepatotoxicity from granulocyte-macrophage colony-stimulating factor administered after autologous bone marrow transplantation.
    Prince HM; Cheng M; Cameron RG; Keating A
    Bone Marrow Transplant; 1995 Jul; 16(1):195-7. PubMed ID: 7581124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engraftment syndrome after autologous hematopoietic stem cell transplant supported by granulocyte-colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor (GM-CSF).
    Akasheh M; Eastwood D; Vesole DH
    Bone Marrow Transplant; 2003 Jan; 31(2):113-6. PubMed ID: 12621492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective economic evaluation accompanying a trial of GM-CSF/IL-3 in patients undergoing autologous bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma. IL-3 BMT Study Team.
    Schulman KA; Dorsainvil D; Yabroff KR; DiCesare J; Felser J; Eisenberg JM; Glick HA
    Bone Marrow Transplant; 1998 Mar; 21(6):607-14. PubMed ID: 9543065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GM-CSF as an adjunct to autologous bone marrow transplantation.
    Gulati S; Bennett C; Phillips J; Van-Poznak C
    Stem Cells; 1993 Jan; 11(1):20-5. PubMed ID: 8457776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.
    Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R
    Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokine therapy after bone marrow transplantation.
    Dix SP; Gilmore CE
    Pharmacotherapy; 1996; 16(4):593-608. PubMed ID: 8840365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progenitor content of autologous grafts: mobilized bone marrow vs mobilized blood.
    Dahl E; Burroughs J; DeFor T; Verfaillie C; Weisdorf D
    Bone Marrow Transplant; 2003 Sep; 32(6):575-80. PubMed ID: 12953129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes and graft characteristics in pediatric matched sibling donor transplants using granulocyte colony-stimulating factor-primed bone marrow and steady-state bone marrow.
    Chiang KY; Haight A; Horan J; Olson E; Gartner A; Hartman D; Youssef S; Worthington-White D
    Pediatr Transplant; 2007 May; 11(3):279-85. PubMed ID: 17430483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF; Chan HO
    Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjunct to autologous bone marrow transplantation (ABMT) in hematology. Results of the interim analysis of the Schering-Plough/Sandoz International trial and considerations on increased safety in the transplant ward.
    Gorin NC; Fouillard L
    Pathol Biol (Paris); 1992 Nov; 39(9):954-5. PubMed ID: 1538950
    [No Abstract]   [Full Text] [Related]  

  • 13. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature.
    Jacoub JF; Suryadevara U; Pereyra V; Colón D; Fontelonga A; Mackintosh FR; Hall SW; Ascensão JL
    Exp Hematol; 2006 Nov; 34(11):1443-50. PubMed ID: 17046563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GM-CSF versus G-CSF: engraftment characteristics, resource utilization, and cost following autologous PBSC transplantation.
    Zumberg MS; Leather HL; Nejame C; Meyer C; Wingard JR
    Cytotherapy; 2002; 4(6):531-8. PubMed ID: 12568989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of GM-CSF in bone marrow transplantation.
    Vose JM; Armitage JO
    Behring Inst Mitt; 1991 Dec; (90):39-43. PubMed ID: 1801689
    [No Abstract]   [Full Text] [Related]  

  • 16. The effect of granulocyte-macrophage colony stimulating factor on paroxysmal nocturnal hemoglobinuria: a case report.
    Webb DI; Bundtzen JL
    Alaska Med; 1993; 35(3):216-7, 224. PubMed ID: 8109693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The implications of granulocyte-monocyte colony-stimulating factor (GM-CSF) in cytotoxicity of bone marrow transplantation.
    Toren A; Nagler A
    Cytokines Cell Mol Ther; 1998 Sep; 4(3):199-206. PubMed ID: 9825845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulfasalazine induced agranulocytosis treated with granulocyte-macrophage colony stimulating factor.
    Kuipers EJ; Vellenga E; de Wolf JT; Hazenberg BP
    J Rheumatol; 1992 Apr; 19(4):621-2. PubMed ID: 1350640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation.
    Bashey A; Donohue M; Liu L; Medina B; Corringham S; Ihasz A; Carrier E; Castro JE; Holman PR; Xu R; Law P; Ball ED; Lane TA
    Transfusion; 2007 Nov; 47(11):2153-60. PubMed ID: 17958545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products.
    Lonial S; Hicks M; Rosenthal H; Langston A; Redei I; Torre C; Duenzl M; Feinstein B; Cherry J; Waller EK
    Biol Blood Marrow Transplant; 2004 Dec; 10(12):848-57. PubMed ID: 15570253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.